Infant Bacterial Therapeutics (IBT) Q4 2024 earnings summary

Executive summary

• No net sales were recorded for 2024; the company remains pre-revenue as it advances its lead drug candidate, IBP-9414, through late-stage development and regulatory processes.

• The pivotal Phase III clinical program for IBP-9414 was completed in July 2024, with results showing no significant effect on primary endpoints but a significant reduction in all-cause mortality as a secondary endpoint.

• Intensive regulatory engagement with the FDA occurred in Q4 2024, with preparations underway for a Biologics License Application (BLA) submission in 2025.

• The company is preparing for potential product launch and market entry, focusing on the US and seeking partners for other regions.

Financial highlights

• Operating loss for Q4 2024 was KSEK -37,445, an improvement from KSEK -45,652 in Q4 2023; full-year operating loss was KSEK -145,343, compared to KSEK -134,617 in 2023.

• Result after tax for 2024 was KSEK -136,905, compared to KSEK -123,068 in 2023.

• Cash flow for 2024 was KSEK -111,120, a significant decrease from KSEK -4,704 in 2023, reflecting increased R&D and preparation costs.

• Cash and cash equivalents at year-end 2024 were KSEK 223,388, down from KSEK 329,064 at year-end 2023.

• Equity per share at year-end 2024 was SEK 12.64, down from SEK 22.65 at year-end 2023; equity ratio decreased to 71% from 87%.

Outlook and guidance

• BLA submission to the FDA is planned for spring 2025, with potential approval optimistically expected within the year, depending on regulatory review timelines.

• Preparations for commercial launch of IBP-9414 are intensifying, including market research and production planning.

• The company aims to handle US sales directly and seek distribution partners for other regions, with increased partnering activity expected in 2025.